AR028840A1 - Un polimorfo v de torasemida, un proceso para su preparacion y forma farmaceutica que lo contiene - Google Patents

Un polimorfo v de torasemida, un proceso para su preparacion y forma farmaceutica que lo contiene

Info

Publication number
AR028840A1
AR028840A1 ARP000103199A ARP000103199A AR028840A1 AR 028840 A1 AR028840 A1 AR 028840A1 AR P000103199 A ARP000103199 A AR P000103199A AR P000103199 A ARP000103199 A AR P000103199A AR 028840 A1 AR028840 A1 AR 028840A1
Authority
AR
Argentina
Prior art keywords
torasemide
polymorph
preparation
torasemida
pharmaceutical form
Prior art date
Application number
ARP000103199A
Other languages
English (en)
Inventor
Darko Filic
Miljenko Dumic
Bozena Klepic
Aleksandar Danilovski
Marijan Tudja
Original Assignee
Pliva Pharm & Chem Works
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliva Pharm & Chem Works filed Critical Pliva Pharm & Chem Works
Publication of AR028840A1 publication Critical patent/AR028840A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente se refiere a una forma cristalina de N-(1-metilamino carbonil)-4-(3-metil-fenilamino)-3-piridinsulfonamida, en adelante "Torasemida" y en especial a un polimorfo V de torasemida, a un proceso para su preparacion, a su utilizacion como materia prima para preparar modificaciones cristalinas I y III de torasemida, a modificaciones amorfas de torasemida, a sales de torasemida farmacéuticamente aceptables, a formas farmacéuticas que contienen dicho nuevo polimorfo V de torasemida como ingrediente activo, y a su utilizacion.
ARP000103199A 2000-05-19 2000-06-26 Un polimorfo v de torasemida, un proceso para su preparacion y forma farmaceutica que lo contiene AR028840A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HR20000328A HRP20000328A2 (en) 2000-05-19 2000-05-19 Novel polymorph v of torasemide

Publications (1)

Publication Number Publication Date
AR028840A1 true AR028840A1 (es) 2003-05-28

Family

ID=10947111

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000103199A AR028840A1 (es) 2000-05-19 2000-06-26 Un polimorfo v de torasemida, un proceso para su preparacion y forma farmaceutica que lo contiene

Country Status (32)

Country Link
US (2) US7241782B1 (es)
EP (1) EP1283828B1 (es)
JP (1) JP2003533512A (es)
KR (1) KR20030016267A (es)
CN (1) CN1520403A (es)
AP (1) AP2002002679A0 (es)
AR (1) AR028840A1 (es)
AT (1) ATE342890T1 (es)
AU (1) AU2000274381A1 (es)
BG (1) BG107407A (es)
BR (1) BR0015877A (es)
CA (1) CA2409699A1 (es)
CZ (1) CZ20024104A3 (es)
DE (1) DE60031450T2 (es)
DZ (1) DZ3356A1 (es)
EA (1) EA005003B1 (es)
EE (1) EE200200637A (es)
GE (1) GEP20043321B (es)
HR (1) HRP20000328A2 (es)
HU (1) HUP0302135A2 (es)
IL (1) IL152810A0 (es)
IS (1) IS6620A (es)
MA (1) MA25748A1 (es)
MX (1) MXPA02011402A (es)
NO (1) NO20025509L (es)
NZ (1) NZ522544A (es)
PL (1) PL358257A1 (es)
SK (1) SK17712002A3 (es)
TR (1) TR200202544T2 (es)
WO (1) WO2001087841A1 (es)
YU (1) YU84202A (es)
ZA (1) ZA200209181B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU781461C (en) * 1999-08-11 2006-02-23 Teva Pharmaceutical Industries Ltd. Torsemide polymorphs
IN192178B (es) 2001-08-03 2004-03-06 Ranbaxy Lab
US7067385B2 (en) * 2003-09-04 2006-06-27 Micron Technology, Inc. Support for vertically oriented capacitors during the formation of a semiconductor device
CN1824647B (zh) * 2005-02-22 2011-04-20 田边三菱制药株式会社 (±)2-(二甲基氨基)-1-{[O-(m-甲氧基苯乙基)苯氧基]甲基}乙基氢琥珀酸酯盐酸盐的晶体
CN100421662C (zh) * 2005-11-08 2008-10-01 周卓和 托拉塞米分散片及其制备方法和应用
CN104370805B (zh) * 2013-08-13 2016-09-07 天津汉瑞药业有限公司 托拉塞米化合物
CN105949115A (zh) * 2016-05-26 2016-09-21 南京正科医药股份有限公司 一种新晶型托拉塞米
CN115417810B (zh) * 2022-09-22 2023-10-10 南京正科医药股份有限公司 一种托拉塞米晶型ⅰ的精制方法
CN117486789A (zh) * 2023-12-29 2024-02-02 江西中医药大学 一种托拉塞米共晶盐及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4055650A (en) 1974-04-17 1977-10-25 A. Christiaens Societe Anonyme Certain 4-phenoxy(or phenylthio)-3-n-acylated-sulfonamido-pyridines
GB1477664A (en) 1974-04-17 1977-06-22 Christiaens Sa A Pyridine derivatives
US4476248A (en) * 1983-02-28 1984-10-09 The Upjohn Company Crystallization of ibuprofen
IN182496B (es) * 1996-02-20 1999-04-17 Reddy Research Foundation
HRP980532B1 (en) * 1998-10-02 2005-06-30 Pliva Novel crystalline torasemide modification
US5914336A (en) * 1998-06-02 1999-06-22 Boehringer Mannheim Gmbh Method of controlling the serum solubility of orally administered torasemide and composition relating thereto

Also Published As

Publication number Publication date
IS6620A (is) 2002-11-14
NO20025509D0 (no) 2002-11-15
EA005003B1 (ru) 2004-10-28
EA200201236A1 (ru) 2003-04-24
AP2002002679A0 (en) 2002-12-31
BR0015877A (pt) 2003-04-29
NO20025509L (no) 2002-11-15
YU84202A (sh) 2006-05-25
CZ20024104A3 (cs) 2003-04-16
EP1283828B1 (en) 2006-10-18
HRP20000328A2 (en) 2002-02-28
MXPA02011402A (es) 2003-06-06
DZ3356A1 (en) 2001-11-22
GEP20043321B (en) 2004-04-13
DE60031450D1 (de) 2006-11-30
ATE342890T1 (de) 2006-11-15
EP1283828A1 (en) 2003-02-19
PL358257A1 (en) 2004-08-09
US7241782B1 (en) 2007-07-10
NZ522544A (en) 2004-07-30
SK17712002A3 (sk) 2003-05-02
HUP0302135A2 (hu) 2003-10-28
CA2409699A1 (en) 2001-11-22
JP2003533512A (ja) 2003-11-11
BG107407A (en) 2004-01-30
KR20030016267A (ko) 2003-02-26
CN1520403A (zh) 2004-08-11
IL152810A0 (en) 2003-06-24
ZA200209181B (en) 2004-02-12
TR200202544T2 (tr) 2003-03-21
US20070238759A1 (en) 2007-10-11
EE200200637A (et) 2004-04-15
AU2000274381A1 (en) 2001-11-26
MA25748A1 (fr) 2003-04-01
DE60031450T2 (de) 2007-09-20
WO2001087841A1 (en) 2001-11-22

Similar Documents

Publication Publication Date Title
SV2002000321A (es) Una nueva forma cristalina del acido n-[4-[2-(2- amino-4,7-dihidro-4-oxo-3h-pirrolo[2,3-d]pirimidin -5-il)etil]benzoil]-l-glutamico y procedimiento para su preparacion ref. x-11969
IL179719A0 (en) Process for preparation of amorphous form of drug
ECSP045193A (es) "nuevos compuestos heterociclicos, activos como inhibidores de beta-lactamasas"
RS51569B (en) COMPOSITIONS CONTAINING CRYSTAL TRANS - (+/-) - DELTA-9-TETRAHYDROCANABINOL
CO5580767A2 (es) Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas y procedimientos para su uso
CL2004001267A1 (es) Compuestos derivados de quinazolina, inhibidor de quinasa; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso para preparar un medicamento para tratar trastornos proliferativos celulares tales como ateroesclerosis,
NI200700068A (es) Clorhidrato de 4-[[4-[[4-(2-cianoetenil)-2,6- dimetilfenil]amino]-2- pirimidinil]amino] benzonitrilo
AR028840A1 (es) Un polimorfo v de torasemida, un proceso para su preparacion y forma farmaceutica que lo contiene
UA96622C2 (ru) Твердые лекарственные формы, которые содержат алискирен, изготовленные способом сухого гранулирования
PL1853232T3 (pl) Trwałe postaci krystaliczne mesylanu bifeprunoksu, postaci dawkowania oraz sposoby ich stosowania
WO2009038412A3 (en) Beta-secretase inhibiting compounds
UY27673A1 (es) Procedimiento para la preparación de un producto de inhalación en polvo que contiene una sal del antagonista de cgrp,
DE60102590D1 (de) Darreichungsformen zur behandlung von oralen mykosen
NO20023551D0 (no) Ibuprofen-inneholdende aktivt middel-preparat
GEP20156410B (en) Formulation comprising phenylaminopyrimidine derivative as active agent
WO2008074833A3 (en) Compounds
DK1624869T3 (da) Doseringsform indeholdende pantoprazol som aktiv bestanddel
DE60131416D1 (de) Chirale fluorochinolizinon arginine salze
AR023788A1 (es) Modificacion amorfa de torasemida
PE20011080A1 (es) Uso de mirtazapina para el tratamiento de trastornos del sueno
FR2911278B1 (fr) Procede d'obtention d'un actif cosmetique depigmentant, principe actif obtenu et compositions l'incluant
WO2008097539A3 (en) Multi-modal absorption, medicine-delivery lozenge, and use thereof
SE0302924D0 (sv) Pharmaceutical composition having a cationic excipient
DK1660495T3 (da) Benzoquinolizin-2-carboxylsyreargininsalt,tetrahydrat
WO2004087102A3 (en) A process for preparing a pharmaceutical active ingredient with high specific surface area

Legal Events

Date Code Title Description
FB Suspension of granting procedure